A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2- negative primary breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 2, 2014, Pages 229-238

  Masuda, N ^a   Higaki, K ^b   Takano, T ^c   Matsunami, N ^d   Morimoto, T ^e   Ohtani, S ^b   Mizutani, M ^a   Miyamoto, T ^f   Kuroi, K ^g   Ohno, S ^h   Morita, S ⁱ   Toi, M ^j  

^a OSAKA NATIONAL HOSPITAL   (Japan)

^b HIROSHIMA CITY HOSPITAL   (Japan)

^c TORANOMON HOSPITAL   (Japan)

^d OSAKA ROSAI HOSPITAL   (Japan)

^e Yao Municipal Hospital   (Japan)

^f GUNMA PREFECTURAL CANCER CENTER   (Japan)

^g TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^h NATIONAL KYUSHU CANCER CENTER   (Japan)

ⁱ YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^j KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Capecitabine; Metronomic chemotherapy; Oral cyclophosphamide; pCR; Triple negative breast cancer; Weekly paclitaxel

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CAPECITABINE; CREATININE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; HORMONE RECEPTOR; PACLITAXEL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; EVALUATION STUDY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HAND FOOT SYNDROME; HEMORRHOID; HISTOPATHOLOGY; HUMAN; INTENTION TO TREAT ANALYSIS; INTERSTITIAL PNEUMONIA; LEUKOCYTE COUNT; LEUKOPENIA; MALAISE; MASTECTOMY; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; PARTIAL MASTECTOMY; PHASE 2 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; STEROID THERAPY; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84907597678     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2492-y     Document Type: Article

References (47)

1. Iwase H, Kurebayashi J, Tsuda H et al (2010) Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer 17:118-124
2. Japanese Breast Cancer Society (2004) Investigative Report on Registration of Breast Cancer Patients in Japan [in Japanese]. No. 35
3. Kang SP, Martel M, Harris LN (2008) Triple negative breast cancer: current understanding of biology and treatment options. Curr Opin Obstet Gynecol 20:40-46
4. Bauer KR, Brown M, Cress RD et al (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 109:1721-1728 (Pubitemid 46668532)
5. Liedtke C, Maouni D, Hoss KR et al (2008) Response to neoadjuvant therapy and long term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275-1281
6. Bidard FC, Matthieu MC, Chollet P et al (2008) p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol 19:1261-1265 (Pubitemid 351916575)
7. Carey LA, Dees EC, Sawyer L et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334 (Pubitemid 46698581)
8. Keam B, Im SA, Kim HJ et al (2007) Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer 7:203
9. Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685 (Pubitemid 41170290)
10. Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer; therapeutic options. Lancet Oncol 8:235-244 (Pubitemid 46291713)
11. Ohno S, Mitsuyama S, Tamura K et al (2007) Dose of capecitabine and cyclophosphamide combination therapy in patients with metastatic breast cancer. Anticancer Res 27:1009-1013 (Pubitemid 46587014)
12. Yoshimoto M, Takao S, Hirata M et al (2012) Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer. Cancer Chemother Pharmacol 70:331-338
13. O'Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812-2823 (Pubitemid 34651510)
14. Sawada N, Fujimoto-Ouchi K, Ishikawa T et al (2002) Antitumor activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models. Proc Am Assoc Cancer Res 43:1088 (abstract #5388)
15. Endo M, Shinbori N, Fukase Y et al (1999) Induction of thymidine phosphorylase expression and enhancement of efficacy by cyclophosphamide in mammary tumor models. Int J Cancer 83:127-134 (Pubitemid 29409488)
16. Taguchi T, Yamamoto D, Masuda N et al (2013) Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609. Cancer Chemother Pharmacol 71:741-747
17. Masuda N, Nakayama T, Yamamura J et al (2010) Phase I study of combination therapy with weekly paclitaxel and cyclophosphamide for advanced recurrent breast cancer. Cancer Chemother Pharmacol 66:89-94
18. Dellapasqua S, Bertolini F, Bagnardi V et al (2008) Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26:4899-4905
19. Seidman AD, Berry D, Cirrincione C et al (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642-1649
20. Mauri D, Kamposioras K, Tsali L et al (2010) Overall survival benefit for weekly versus three-weekly taxanes regimens in advanced breast cancer: a meta-analysis. Cancer Treat Rev 36:69-74
21. Walker P (2013) Phase II trial of neoadjuvant metronomic chemotherapy in triple-negative breast cancer (protocol ID: LJCC 07-03, NCT00542191), http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=573471& protocolsearchid=5968740&version=healthprofessional. Accessed 2 Oct 2013
22. Glode LM, Barqawi A, Crighton F et al (2003) Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 98:1643-1648 (Pubitemid 37238620)
23. Emmenegger U, Man S, Shaked Y et al (2004) A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 64:3994-4000 (Pubitemid 38697315)
24. Colleoni M, Orlando L, Sanna G et al (2006) Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 17:232-238 (Pubitemid 43160111)
25. Bottini A, Generali D, Brizzi MP et al (2006) Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 24:3623-3628 (Pubitemid 46630536)
26. Kerbel RS (2011) Reappraising antiangiogenic therapy for breast cancer. Breast 20:S56-S60
27. Kuroi K, Toi M, Tsuda H et al (2006) Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. Breast Cancer 13:38-48
28. Kimura M, Sano M, Hujimori M et al (2008) Neoadjuvant paclitaxel for operable breast cancer: multicenter phase II trial with clinical outcomes. Anticancer Res 28:1239-1244 (Pubitemid 351578862)
29. Belotti D, Vergani V, Drudis T et al (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2:1843-1849 (Pubitemid 26384151)
30. Milross CG, Mason KA, Hunter NR et al (1996) Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 88:1308-1314 (Pubitemid 26301619)
31. Symmans WF, Volm MD, Shapiro RL et al (2000) Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant chemotherapy. Clin Cancer Res 6:4610-4617 (Pubitemid 32110395)
32. Griffon-Etienne G, Boucher Y, Brekken C et al (1999) Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 59:3776-3782 (Pubitemid 29381886)
33. Milas L, Hunter NR, Mason KA et al (1995) Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res 55:3564-3568
34. Green MC, Buzdar AU, Smith T et al (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23:5983-5992
35. Loesch DM, Greco F, O'Shaughnessy J et al (2007) A randomized multicenter phase III trial comparing doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for high breast cancer. J Clin Oncol 25(suppl 18):517
36. Ellis GK, Barlow WE, Russell CA et al (2006) SWOG 0012, a randomized phase III comparison of standard doxorubicin and cyclophosphamide followed by weekly paclitaxel versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer. Proc Am Soc Clin Oncol 24(suppl 18):537
37. Bari M, D'Andrea MR, Azzarello G et al (2005) Salvage therapy with capecitabine plus weekly paclitaxel in heavily pretreated advanced breast cancer. A multicenter phase II study. Am J Cancer 4:307-313 (Pubitemid 41549735)
38. Blum JL, Dees EC, Chacko A et al (2006) Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 24:4384-4390 (Pubitemid 46630975)
39. Blum JL, Dees EC, Vukelja SJ et al (2007) Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy. Clin Breast Cancer 7:465-470 (Pubitemid 46424283)
40. Nakayama T, Masuda M, Kamigaki S et al (2008) Phase I clinical study of weekly paclitaxel and cyclophosphamide combination therapy for advanced and recurrent breast cancer [in Japanese]. Jpn Soc Clin Oncol 43:508 (abstract OS064-6)
41. Findlay MPN, Riley GA, Ackland S et al (2002) Capecitabine and oral cyclophosphamide: A novel oral treatment combination for advanced cancer. Ann Oncol 13:24 (abstract 86P)
42. Kerbel RS, Klement G, Pritchard KI, Kamen B (2012) Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 13:12-15
43. Lien K, Georgsdottir S, Sivanathan L, Chan K, Emmenegger U (2013) Low-dose metronomic chemotherapy: a systematic literature analysis. Eur J Cancer 49:3387-3395
44. Bear HD, Anderson S, Smith R et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national Surgical Adjuvant Breast and Bowel Project B-27. J Clin Oncol 24:2017-2019
45. von Minckwitz G, Schneeweiss A, Salat C et al (2013) A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). In: 49th ASCO annual meeting (meeting abstract): 1004, Chicago, IL
46. Sikov WM, Berry DA, Perou CM et al (2013) Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). In: 36th annual SABCS (meeting abstract): S5-01, San Antonio, TX
47. von Minckwitz G, Eidtmann H, Rezai M et al (2012) Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 366:299-309